原发性中枢神经系统淋巴瘤脑脊液生物标志物研究进展

Progress of cerebrospinal fluid biomarkers in primary central nervous system lymphoma

原发性中枢神经系统淋巴瘤(PCNSL)是非霍奇金淋巴瘤的亚型之一,大多数病理类型为弥漫大B细胞淋巴瘤。目前PCNSL的诊断金标准是活组织检查以及病理学检查,但因穿刺风险较大、患者依从性问题和缺乏特异性症状等原因,很多患者无法早期诊断。PCNSL对化疗较为敏感,但因很多患者无法耐受大剂量化疗或出现耐药,导致病情进展或复发。因此,寻找和鉴定脑脊液中生物标志物,用于早期诊断、疗效判定和预后监测,对提高PCNSL的诊疗水平尤为关键。

Primary central nervous system lymphoma (PCNSL) is one of the subtypes of non-Hodgkin lymphoma, its most pathological type is diffuse large B-cell lymphoma. At present, the gold standard of PCNSL diagnosis is biopsy and pathological examination, but many patients cannot be diagnosed early due to high risk of puncture, patient compliance problems and lack of specific symptoms. PCNSL is sensitive to chemotherapy, but many patients cannot tolerate high-dose chemotherapy or develop drug resistance, leading to disease progression or recurrence. Therefore, the search and identification of biomarkers in cerebrospinal fluid for early diagnosis, efficacy judgment and prognosis monitoring are particularly important for improving the diagnosis and treatment of PCNSL.